Literature DB >> 21357311

Intermittent positive-pressure breathing after lung surgery.

Corinna Ludwig1, Sebastian Angenendt, Renato Martins, Volker Mayer, Erich Stoelben.   

Abstract

Intermittent positive-pressure breathing is thought to avoid atelectasis and improve pulmonary function after major lung resections. Since no clear scientific data was available to confirm this, our objective was to determine whether atelectasis can be avoided and if postoperative lung function is improved. Prospective analysis was carried out in 135 patients operated on between 2007 and 2009; 55 received intermittent positive-pressure breathing. Pre- and postoperative lung function tests were similar in both groups. Pulmonary complications were observed in 19% of patients without intermittent positive-pressure breathing and 27% of those who received this treatment. We were unable to find evidence that additional improvement in postoperative pulmonary function is achieved when adding intermittent positive-pressure breathing to the standard physical therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21357311     DOI: 10.1177/0218492310394664

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  3 in total

1.  Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients.

Authors:  Maria Fs Torres; Gustavo Jm Porfírio; Alan Pv Carvalho; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2019-03-06

2.  Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis.

Authors:  Peter M Odor; Sohail Bampoe; David Gilhooly; Benedict Creagh-Brown; S Ramani Moonesinghe
Journal:  BMJ       Date:  2020-03-11

3.  Prophylactic continuous positive airway pressure after pulmonary lobectomy: a randomized controlled trial.

Authors:  Alessandro Palleschi; Emilia Privitera; Marta Lazzeri; Sara Mariani; Lorenzo Rosso; Davide Tosi; Paolo Mendogni; Ilaria Righi; Rosaria Carrinola; Matteo Montoli; Marco Reda; Massimo Torre; Luigi Santambrogio; Mario Nosotti
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.